Outset Medical Inc


Outset Medical Inc

  • Price (USD)52.19
  • Today's Change1.37 / 2.70%
  • Shares traded335.38k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 07 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Outset Medical, Inc. is a medical technology company. The Company offers Tablo, a dialysis machine. Tablo offers acute and chronic dialysis. Tablo produces dialysate that’s customized to the patient’s prescription. Its touchscreen guidance and animated instructions enables to train new users. Tablo has integrated water purification and produces dialysis on demand. The other features of Tablo include integrated blood pressure cuff and automated saline bolus and tracking. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels and allows providers to a single platform from the hospital to the home. The three subtypes of hemodialysis that are used in the hospital are Intermittent Hemodialysis (IHD), Slow Low Efficiency Dialysis (SLED) and CRRT. IHD is used at the bedside or an inpatient dialysis unit outside of the ICU, while SLED and CRRT are used in the ICU.

  • Revenue in USD (TTM)49.94m
  • Net income in USD-79.32m
  • Incorporated2003
  • Employees313.00
  • Location
    Outset Medical Inc3052 Orchard DriveSAN JOSE 95134United StatesUSA
  • Phone+1 (971) 563-3083
  • Fax+1 (302) 655-5049
  • Websitehttps://outsetmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Pulmonx Corp33.36m-37.11m1.49bn170.00--6.90--44.80-1.71-1.711.166.07------196,229.40--------66.44---111.25--16.22-15.580.0741--0.4234---55.68------
Cardiovascular Systems Inc228.43m-20.19m1.56bn779.00--5.70--6.84-0.5728-0.57286.236.810.79721.816.68293,240.10-7.04-8.25-8.56-10.1978.6180.57-8.84-7.715.42-13.650.0703---4.635.44-10,580.78---28.11--
Eargo Inc69.15m-30.02m1.63bn238.00--8.38--23.54-0.5217-0.52170.99215.070.53217.7923.67290,563.00-30.67---37.26--68.37---57.63--9.26-18.520.0711--110.90--32.11------
Establishment Labs Holdings Inc90.53m-27.31m1.63bn521.00--22.57--18.06-1.16-1.163.833.060.56451.403.99173,763.90-17.03---19.97--63.0959.08-30.17-53.264.27-4.630.4095---5.4654.580.076------
Luminex Corporation417.40m14.87m1.71bn1.33k114.383.2637.394.090.32270.32279.0711.330.60971.696.80315,015.802.222.762.483.0559.3861.083.634.404.413.140.281872.8624.7311.92243.38-16.60-1.75--
Treace Medical Concepts Inc57.37m-4.31m1.73bn133.00------30.13-0.1554-0.15542.07--------431,315.80--------78.26---6.39----0.189----45.54--12.17------
Avanos Medical Inc714.80m-27.20m2.06bn5.38k--1.63131.072.88-0.5719-0.571914.9126.220.41172.175.25132,862.50-1.57-2.42-1.76-2.8452.2255.53-3.81-7.281.793.230.1253--2.477.03-13.94---22.10--
Heska Corp197.32m-14.40m2.11bn602.00--6.70--10.72-1.73-1.7322.8030.290.61263.488.13327,780.70-4.361.98-4.932.3541.2043.08-7.112.583.12-0.32630.1473--60.8713.54-882.87---28.89--
Fulgent Genetics Inc421.71m214.31m2.12bn429.008.863.619.725.028.248.2417.7920.211.07--4.39983,011.6054.4333.2565.5538.1278.7074.6650.9339.63----0.02570.001,196.46113.1952,243.55--75.67--
Butterfly Network Inc0.00-3.45m2.31bn260.00--1.57-----0.0686-0.06860.007.68------0.00--------------------0.00--------------
Outset Medical Inc49.94m-79.32m2.32bn313.00--6.61--46.48-1.94-1.941.227.69------159,536.70---------26.11---243.30--8.93-49.670.0828--231.18---16.14------
Axonics Inc111.54m-54.92m2.35bn416.00--7.78--21.04-1.50-1.503.027.200.39691.138.53268,113.00-19.54---21.78--60.15---49.24--5.80--0.0684--707.06--31.30------
Owens & Minor, Inc.8.68bn166.57m2.53bn6.30k13.713.219.760.29112.451.54131.5310.472.445.9512.371,378,416.004.69-1.107.90-1.8016.7612.651.92-0.39480.66095.190.5552---7.93-2.80489.98-2.9910.08-60.27
Inmode Ltd231.19m95.24m2.88bn311.0033.549.8030.0612.452.252.255.477.690.81552.5022.22743,376.2033.61--38.03--84.97--41.21--8.62--0.00--31.81--22.71------
Integer Holdings Corp1.04bn67.68m3.11bn7.50k46.122.4321.,064.402.852.293.082.4726.4129.446.545.191.582.710.34970.00-14.686.05-15.30--2.89--
Haemonetics Corporation883.93m108.13m3.12bn3.00k29.104.3415.673.532.112.1117.2514.150.69171.645.56294,249.708.461.9110.282.3748.6245.6012.232.641.908.330.30110.002.161.6639.0935.27-16.79--
Data as of May 07 2021. Currency figures normalised to Outset Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

65.16%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Dec 20206.39m14.92%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20204.66m10.88%
D1 Capital Partners LPas of 31 Dec 20204.58m10.69%
PFM Health Sciences LPas of 31 Dec 20202.91m6.80%
Mubadala Investment Co. PJSC (Investment Management)as of 12 Apr 20212.89m6.75%
Perceptive Advisors LLCas of 31 Dec 20202.85m6.65%
The Vanguard Group, Inc.as of 31 Dec 20201.24m2.91%
AllianceBernstein LPas of 31 Dec 2020907.76k2.12%
TimesSquare Capital Management LLCas of 31 Dec 2020793.92k1.86%
BlackRock Fund Advisorsas of 31 Dec 2020672.94k1.57%
More ▼
Data from 31 Dec 2020 - 12 Apr 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.